AnaptysBio (NASDAQ:ANAB) Rating Reiterated by Leerink Partnrs

AnaptysBio (NASDAQ:ANAB)‘s stock had its “outperform” rating reaffirmed by Leerink Partnrs in a research note issued on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for AnaptysBio’s Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

A number of other research firms also recently weighed in on ANAB. BTIG Research assumed coverage on AnaptysBio in a report on Monday, February 26th. They set a “buy” rating and a $55.00 price objective on the stock. Stifel Nicolaus assumed coverage on AnaptysBio in a report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective on the stock. Piper Sandler assumed coverage on AnaptysBio in a report on Friday, February 16th. They set an “overweight” rating and a $80.00 price objective on the stock. Wedbush raised AnaptysBio from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $20.00 to $34.00 in a report on Tuesday, March 12th. Finally, SVB Leerink assumed coverage on AnaptysBio in a report on Tuesday. They set an “outperform” rating and a $47.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, AnaptysBio presently has an average rating of “Moderate Buy” and an average price target of $46.22.

AnaptysBio Stock Up 0.6 %

Shares of ANAB opened at $21.47 on Tuesday. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $27.50. The firm has a market capitalization of $574.54 million, a price-to-earnings ratio of -3.53 and a beta of -0.30. The stock’s 50-day moving average price is $23.38 and its 200 day moving average price is $20.55.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.74) by $0.15. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. The firm had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. Equities research analysts expect that AnaptysBio will post -6.25 EPS for the current year.

Insider Buying and Selling

In related news, insider Eric J. Loumeau sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the insider now owns 3,240 shares in the company, valued at approximately $81,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other AnaptysBio news, CEO Daniel Faga sold 145,940 shares of the company’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the sale, the chief executive officer now owns 752,087 shares in the company, valued at approximately $17,132,541.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric J. Loumeau sold 5,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the sale, the insider now owns 3,240 shares of the company’s stock, valued at approximately $81,000. The disclosure for this sale can be found here. Insiders sold 157,005 shares of company stock worth $3,586,199 in the last quarter. Insiders own 35.50% of the company’s stock.

Institutional Trading of AnaptysBio

Several institutional investors and hedge funds have recently made changes to their positions in ANAB. Swiss National Bank raised its position in shares of AnaptysBio by 7.9% during the 1st quarter. Swiss National Bank now owns 42,300 shares of the biotechnology company’s stock valued at $1,047,000 after acquiring an additional 3,100 shares during the last quarter. MetLife Investment Management LLC increased its position in shares of AnaptysBio by 57.0% in the 1st quarter. MetLife Investment Management LLC now owns 11,043 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 4,009 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of AnaptysBio by 11.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 891,851 shares of the biotechnology company’s stock valued at $22,064,000 after buying an additional 88,457 shares in the last quarter. Ergoteles LLC bought a new stake in shares of AnaptysBio in the 1st quarter valued at $479,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of AnaptysBio by 4.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 142,131 shares of the biotechnology company’s stock valued at $3,517,000 after buying an additional 5,819 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.